 to bring safe and effective drugs to market. Now, we briefly mentioned this accelerated approval program earlier in the show, but I wonder, Dr. Newell, what do you say to that statement from the FDA that it is encouraging input from a variety of stakeholders to improve some of these post-transplant medications?